Chiesi Wins EU Nod For COPD Triple Combo, But Partner Is Predicted For Launch
Chiesi's triple combination therapy for COPD, Trimbow, has secured its first approval globally after winning a positive recommendation from the CHMP for its use in Europe – but analysts expect a respiratory partner will be required to launch the product.
You may also be interested in...
Ahead of a regulatory verdict in the US, GSK's triple combination therapy for COPD, Trelegy Ellipta, has won a positive recommendation in Europe.
There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.